Lesson
Definition, Staging, and Phenotype
Heart failure is a clinical syndrome with objective cardiac support. Stage describes disease progression, while ejection fraction describes current or historical ventricular behavior.
- Clinical syndrome
- Stages A through D
- Ejection-fraction phenotypes
- Limits of ejection fraction
Prevent injury
Find structure or biomarkers
Treat disease and syndrome
Refer before the window closes
Require clinical and objective evidence
Dyspnea, fatigue, edema, orthopnea, and exercise intolerance are important but nonspecific. Structural or functional cardiac abnormality plus elevated filling pressures, natriuretic peptides, imaging, or objective congestion supports the syndrome. Pulmonary, renal, hepatic, venous, hematologic, and deconditioning mimics remain active alternatives.
Use stages to record progression
Stage A identifies risk without structural disease or symptoms. Stage B identifies pre-heart failure through structure, function, filling pressure, or biomarker evidence without symptoms. Stage C includes current or prior symptoms with structural disease. Stage D describes advanced symptoms or recurrent instability despite treatment.
Use ejection fraction as a second axis
HFrEF is 40 percent or less, HFmrEF is 41 to 49 percent, HFpEF is at least 50 percent, and HFimpEF requires a prior value of 40 percent or less followed by a value above 40 percent. Document timing, method, loading conditions, and prior nadir.
Do not confuse a ratio with health
Ejection fraction does not directly measure contractility, stroke volume, filling pressure, reserve, or tissue integrity. A small stiff ventricle can eject a preserved fraction while delivering low stroke volume at high pressure. Serial volume, strain, valve, pressure, and etiologic data complete the picture.
Quick check
Checking for saved practice…
Lesson
Pump Mechanics and Remodeling
The heart is a coupled pressure, volume, timing, valve, and vascular system. Heart failure appears when compensation can no longer preserve output without excessive pressure or biologic cost.
- Pressure-volume loop
- Preload and compliance
- Afterload and contractility
- Systolic and diastolic dysfunction
Pressure is not volume
Separate from load
Afterload is composite
Prepare the next beat
Read the pressure-volume loop as a story
Filling, isovolumic contraction, ejection, and isovolumic relaxation form the loop. Width represents stroke volume and enclosed area approximates stroke work. End-systolic and diastolic relationships help separate contractile state from chamber compliance and loading.
Separate preload from filling pressure
Preload reflects fiber stretch near end diastole, while measured pressure depends heavily on compliance. A stiff ventricle can reach high pressure with little added volume. Rhythm, filling time, venous tone, pericardial constraint, and atrial contraction modify the relationship.
Treat afterload as a composite
The ventricle ejects against arterial pressure, resistance, impedance, valve obstruction, and wall stress. Contractility is the intrinsic force-generating state, but observed ejection remains load dependent. A cuff pressure alone cannot describe the total load.
Connect mechanics to remodeling
Systolic dysfunction often raises end-systolic volume and promotes dilation. Diastolic dysfunction raises pressure through impaired relaxation or stiffness. Chronic wall stress, ischemia, inflammation, neurohormonal signaling, and altered matrix biology reshape the ventricle and create electrical and valve consequences.
Quick check
Checking for saved practice…
Lesson
Neurohormonal Compensation
Reduced effective circulation activates sympathetic, RAAS and vasopressin responses that can become harmful when persistent. Natriuretic peptides oppose those effects but may not restore balance.
- Sympathetic activation
- RAAS and vasopressin
- Natriuretic peptides
- Remodeling biology
Perfusion can be reduced despite edema
Immediate support; chronic load
Sodium excretion and vasodilation
Symptoms do not define the substrate
Follow the baroreceptor response
Lower effective perfusion increases sympathetic tone. Heart rate, contractility, venous tone, and vascular resistance support pressure initially. Chronic catecholamine exposure increases oxygen demand, ischemia, receptor dysregulation, calcium stress, arrhythmia, and cell injury.
Follow the kidney response
Reduced effective renal perfusion and sympathetic drive stimulate renin release, leading to angiotensin II and aldosterone activation. Angiotensin II causes vasoconstriction; aldosterone promotes sodium retention and potassium excretion. These responses can support circulation initially, but persistent activation raises afterload, expands congestion and promotes fibrosis. Serum potassium still depends on kidney function and treatment.
Separate sodium retention from free-water retention
Reduced effective circulation can sustain nonosmotic vasopressin release despite edema. Vasopressin increases collecting-duct water reabsorption, so retained water can dilute serum sodium even when total-body sodium is increased. Interpret low sodium with volume status, osmolality and glucose, kidney function, intake, diuretic exposure, neurologic symptoms and the clinical trajectory. Do not assume every low sodium concentration represents sodium depletion.
Interpret the counter-regulatory peptide system
Wall stress stimulates natriuretic peptides that promote sodium excretion and vasodilation and oppose RAAS and sympathetic activation. This counter-regulation can be insufficient in heart failure; it should not be grouped with pathways that directly drive sodium retention and vasoconstriction. BNP and NT-proBNP support diagnosis and prognosis, but age, atrial fibrillation, kidney disease, obesity, acute timing and therapy affect interpretation. An elevated biomarker is contextual evidence, not a stand-alone diagnosis.
See remodeling as biology, not geometry alone
Myocyte hypertrophy and death, altered calcium handling, extracellular-matrix turnover, inflammation, fibrosis, chamber dilation or thickening, and secondary valve regurgitation create a changed substrate. Symptom improvement does not prove structural reversal. Reassess structure and function when a significant clinical change or a treatment or device decision warrants it; routine repeat imaging without a clinical indication is not recommended.
Quick check
Checking for saved practice…
Lesson
Congestion, Perfusion, and Cardiorenal Physiology
Heart failure harms organs through both inadequate forward flow and excessive backward pressure. Venous congestion is an active mechanism, not merely a visible consequence.
- Pulmonary congestion
- Systemic venous pressure
- Cardiorenal syndrome
- Low output and right-heart failure
Interstitial and alveolar edema
Organ back pressure
Perfusion and oxygen delivery
Interpret the trajectory
Trace pulmonary fluid movement
Elevated left-sided filling pressure raises pulmonary capillary hydrostatic force. Lymphatic reserve delays overt edema, then interstitial and alveolar fluid impair compliance and gas exchange. Examination can be insensitive, so imaging, ultrasound, oxygenation, biomarkers, and context matter.
Treat venous pressure as organ load
High right-sided pressure impairs renal filtration gradient, hepatic drainage, gut absorption, lymphatic return, and abdominal organ function. Jugular pressure, edema, ascites, liver tests, right-ventricular imaging, and the clinical trajectory reveal this burden.
Interpret the kidney in motion
Cardiorenal syndrome includes arterial delivery, venous back pressure, neurohormonal signaling, intra-abdominal pressure, nephrotoxins, and intrinsic kidney disease. A small creatinine rise during effective decongestion is not automatically structural injury, while persistent congestion can be more harmful.
Do not equate pressure with flow
Vasoconstriction can preserve blood pressure despite low cardiac output. Cool extremities, narrow pulse pressure, altered mentation, oliguria, lactate, and hepatic injury signal hypoperfusion. The right ventricle is especially sensitive to pulmonary vascular load, ischemia, rhythm, hypoxia, acidemia, and excessive filling.
Quick check
Checking for saved practice…
Lesson
Phenotypes and Diagnostic Reasoning
Heart failure phenotypes organize evidence, but diagnosis remains an iterative process linking symptoms to objective physiology, etiology, precipitant, trajectory, and alternatives.
- HFrEF
- HFpEF and mimics
- Biomarkers and imaging
- Etiology and triggers
Define the cause
Border phenotype
Prove filling-pressure disease
Remission is not cure
Explain reduced ejection fraction
HFrEF can follow ischemia, genetic cardiomyopathy, myocarditis, toxins, tachycardia, valve disease, endocrine or metabolic disease, and chronic loading. Coronary anatomy, scar, family history, exposure, rhythm burden, valves, blood pressure, and reversibility determine the real diagnosis.
Prove preserved-ejection-fraction disease
HFpEF is not preserved ejection fraction plus dyspnea. Supporting filling-pressure or structural and functional evidence is required. Obesity can lower natriuretic peptides, and resting testing can miss exercise-only elevation. Lung disease, anemia, kidney disease, cirrhosis, venous disease, obesity, and deconditioning can mimic it.
Choose the modality that answers the gap
Echocardiography defines chamber, valve, function, strain, and filling clues. Cardiac MRI characterizes scar, inflammation, and infiltration. Coronary testing evaluates ischemia. Exercise echo or invasive hemodynamics can expose latent pressure abnormalities when resting data remain indeterminate.
Find the reason for worsening
Infection, ischemia, arrhythmia, uncontrolled pressure, medication or diet change, kidney injury, anemia, thyroid disease, pulmonary embolism, valve or mechanical complication, and progressive cardiomyopathy are common triggers. Treating fluid without the precipitant invites recurrence.
Reconcile medicines by mechanism
A medication can destabilize heart failure by retaining sodium, reducing kidney perfusion, depressing myocardial function, slowing or accelerating rhythm, raising vascular load, or interfering with effective therapy. Review prescriptions, nonprescription products, supplements, recent additions, dose changes, missed treatment, and access barriers. The mechanism and patient phenotype determine the significance.
Quick check
Checking for saved practice…
Lesson
Trajectory and Advanced Disease
Heart failure assessment is incomplete without a view of direction. Recurrent admissions, declining function, end-organ dysfunction, therapy intolerance, and escalating support signal a narrowing window for advanced care.
- Longitudinal trajectory
- Advanced heart failure
- Referral timing
- Goals and competing risk
Exclude mimics
Use the right modality
Find reversible disease
Escalate at the right time
Measure direction, not one visit
Daily symptoms fluctuate. Hospitalizations, exercise capacity, renal and hepatic trajectory, diuretic escalation, blood pressure, intolerance of disease therapy, ventricular function, arrhythmia, and device events reveal whether the disease is stable, recovering, or advancing.
Recognize advanced physiology early
Persistent severe symptoms, recurrent congestion, low output, hyponatremia, worsening organ function, escalating diuretic requirements, inability to tolerate therapy, repeated shocks, or dependence on inotropes or temporary support should trigger specialist evaluation.
Refer before options disappear
Transplant, durable mechanical support, complex device or valve intervention, home support, and structured palliative care require time and organ reserve. Waiting for overt shock can allow frailty, kidney injury, liver injury, or malnutrition to close the window.
Integrate goals with physiology
Expected benefit depends on reversibility, competing disease, cognition, frailty, social support, adherence barriers, and what outcomes matter to the patient. Palliative care can accompany disease-directed treatment and is not limited to the final days of life.
Quick check
Checking for saved practice…
Module practice
Check the connections.
Each attempt draws 10 questions from the complete 120 question bank.
Each attempt draws a fresh set and rearranges the answer choices.
References
Current clinical foundation.
Core source material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.
- Ball S. Endotext: Hyponatremia, 2018
- Hall ME and colleagues. Endotext: Hormones of the Cardiovascular System, 2015
- van Berlo JH and colleagues. Cardiac Growth and Remodeling, JCI, 2013
- NICE NG106: Chronic heart failure, recommendations amended 2025
- Mullens W and colleagues. Venous congestion and worsening renal function in advanced decompensated heart failure, JACC 2009
- AHA/ACC/HFSA Heart Failure Guideline, 2022 official slide set
- American College of Cardiology. 2022 AHA, ACC, and HFSA Heart Failure Guideline
- American Heart Association. 2022 Heart Failure Guideline
- American College of Cardiology. 2026 HFpEF Expert Consensus
- American College of Cardiology. 2024 Hospitalized Heart Failure Expert Consensus Update